Answers are grounded in this paper and cite their sources.
Review of hydrocolloid systems highlights controlled release and biocompatibility in pharmaceuticals and cosmetics, suggesting advances in delivery mechanisms.
Hydrocolloid-based and hydrocolloid-dominant hybrid matrices have developed from conventional rheology modifiers into functional platforms for pharmaceutical and cosmetic delivery. This review focuses on systems in which hydrocolloid chemistry, hydration, ionisation, bioadhesion, and network architecture determine swelling, mechanical behaviour, biocompatibility, and controlled release. The discussion covers alginate, chitosan, hyaluronic acid, pectin, carrageenan, dextran, gellan gum, collagen, cellulose derivatives, and selected hybrid architectures in which synthetic or semi-synthetic components provide a defined responsive function. Rather than treating all smart polymers as a single class, the review compares how pH, enzymatic, redox/ROS, thermo-responsive, magnetic, optical, ultrasound-mediated, and multi-trigger mechanisms operate within hydrocolloid-rich matrices. Pharmaceutical examples are considered across oral, transdermal, injectable depot, wound-healing, and regenerative applications, while cosmetic and cosmeceutical systems are discussed in relation to active stabilisation, dermal residence, barrier support, and personalised skincare. By linking material class, trigger mechanism, route of administration, and translational constraints, the review identifies the main advantages of hydrocolloids as delivery matrices as well as their current limitations, including burst release, modest mechanical strength, hydrophobic-drug loading challenges, sterilisation sensitivity, source variability, and regulatory complexity.
No takes yet. Share an insight, caveat, or question.
Khachatryan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: